SPTLC2 Antibody

What is SPTLC2 and why is it significant in biomedical research?

SPTLC2 represents the long chain base subunit 2 of serine palmitoyltransferase, a critical enzyme in sphingolipid biosynthesis. In humans, it exists as a canonical protein of 562 amino acid residues with a mass of approximately 62.9 kDa, primarily localized in the endoplasmic reticulum (ER) . As a member of the Class-II pyridoxal-phosphate-dependent aminotransferase protein family, SPTLC2 plays essential roles in adipose tissue development and lipid metabolism . Its significance extends to neuropathology, with the SPTLC2 gene being directly associated with hereditary sensory neuropathy . The protein is widely expressed across diverse tissue types, making it a valuable target for investigating multiple physiological processes and pathological conditions .

What are the primary applications for SPTLC2 antibodies in research?

SPTLC2 antibodies are employed across several immunodetection techniques. Western blotting represents the most widespread application, with extensive validation across multiple cell lines including A549, HEK-293, HT-29, HepG2, and NIH/3T3 . Immunohistochemistry (IHC) has been validated for human colon tissue and similar samples . Additional validated applications include:

The versatility of these applications makes SPTLC2 antibodies valuable tools for investigating protein expression, localization, and interactions in diverse experimental contexts .

What species reactivity can researchers expect with SPTLC2 antibodies?

Commercial SPTLC2 antibodies have demonstrated confirmed reactivity with human and mouse samples . Existing literature also cites reactivity with rat samples, though validation may vary between antibody suppliers . SPTLC2 gene orthologs have been identified across multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken, suggesting potential cross-reactivity that may be exploitable for comparative studies . When working with species beyond human and mouse, researchers should conduct preliminary validation experiments to confirm reactivity and specificity before proceeding with full-scale investigations.

How should researchers optimize Western blot protocols for SPTLC2 detection?

Optimal Western blot detection of SPTLC2 requires specific protocol adjustments. The recommended antibody dilution range is 1:1000-1:6000, though optimal concentration should be determined empirically for each experimental system . SPTLC2 typically appears at 55-65 kDa on Western blots, with the calculated molecular weight being 63 kDa . For cell and tissue lysate preparation, standard RIPA buffer supplemented with protease inhibitors is generally effective. Sample loading of 20-40 μg total protein typically provides sufficient signal without background issues.

Optimization protocol:

• Begin with a 1:2000 dilution for initial testing

• Use 5% non-fat dry milk in TBST for blocking (1 hour at room temperature)

• Incubate with primary antibody overnight at 4°C

• Wash extensively (4 × 5 minutes) with TBST

• Incubate with HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

• Develop using enhanced chemiluminescence detection

When troubleshooting poor signal, increasing antibody concentration or extending incubation time may improve results. If background is problematic, more stringent washing and higher dilution of primary antibody are recommended .

What are the essential considerations for immunohistochemistry using SPTLC2 antibodies?

Successful immunohistochemical detection of SPTLC2 requires careful attention to tissue preparation and antigen retrieval. For formalin-fixed paraffin-embedded (FFPE) sections, the recommended dilution range is 1:50-1:500 . Antigen retrieval is crucial, with TE buffer at pH 9.0 being the primary recommended method; citrate buffer at pH 6.0 provides an alternative approach .

For optimal IHC results with SPTLC2 antibodies:

• Cut FFPE sections at 4-6 μm thickness

• Deparaffinize and rehydrate following standard protocols

• Perform heat-induced epitope retrieval using TE buffer (pH 9.0) for 15-20 minutes

• Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

• Apply protein blocking solution for 30 minutes

• Incubate with primary antibody (starting at 1:100 dilution) overnight at 4°C

• Apply appropriate detection system (e.g., HRP-polymer) following manufacturer's recommendations

• Develop with DAB substrate and counterstain with hematoxylin

SPTLC2 typically shows cytoplasmic staining with enrichment in perinuclear regions, consistent with its ER localization . Human colon tissue serves as a positive control tissue for validation experiments .

How can researchers validate SPTLC2 antibody specificity in experimental systems?

Validation of SPTLC2 antibody specificity is essential for generating reliable data. Multiple complementary approaches should be employed:

• Genetic validation: Use SPTLC2 knockout or knockdown systems as negative controls. Several publications have utilized this approach for specificity validation .

• Peptide competition assay: Pre-incubate the antibody with a blocking peptide (typically the immunogen) before application to demonstrate signal reduction.

• Molecular weight verification: Confirm the observed band appears at the expected molecular weight (55-65 kDa) .

• Cross-validation: Compare results from multiple antibodies targeting different epitopes of SPTLC2.

• Tissue/cell line panel testing: Verify expression patterns across tissues and cell lines with known SPTLC2 expression profiles. Validated positive systems include A549 cells, HEK-293 cells, HT-29 cells, HepG2 cells, NIH/3T3 cells, and mouse brain tissue .

By employing multiple validation strategies, researchers can establish confidence in antibody specificity and experimental results.

How should researchers design experiments to study SPTLC2's role in lipid metabolism?

Investigating SPTLC2's functions in lipid metabolism requires multi-faceted experimental approaches. An effective experimental design should include:

• Expression manipulation studies:

  • siRNA knockdown or CRISPR-Cas9 knockout of SPTLC2

  • Comparison of wild-type vs. mutant SPTLC2 (particularly disease-associated variants)

  • Rescue experiments with exogenous SPTLC2 expression

• Metabolic profiling:

  • Lipidomic analysis using LC-MS/MS to quantify sphingolipid species

  • Analysis of ceramide:sphingomyelin ratio changes upon SPTLC2 manipulation

  • Pulse-chase experiments with isotope-labeled serine to track de novo sphingolipid synthesis

• Functional assays:

  • Measurement of serine palmitoyltransferase enzymatic activity

  • Assessment of ER stress markers (BiP, CHOP, XBP1 splicing)

  • Evaluation of cellular responses to lipotoxicity challenges

• Protein interaction studies:

  • Co-immunoprecipitation of SPTLC2 with known binding partners

  • Proximity ligation assays to confirm interactions in situ

  • FRET/BRET approaches for dynamic interaction studies

When designing these experiments, it's crucial to include proper controls and to evaluate multiple timepoints as lipid metabolic changes may develop gradually following SPTLC2 perturbation.

What controls are essential when studying SPTLC2 in neuropathy models?

The association between SPTLC2 and neuropathy necessitates rigorous experimental design when studying this relationship. Essential controls include:

• Genetic controls:

  • Wild-type controls alongside disease-associated SPTLC2 mutants

  • Heterozygous models to mirror the dominant inheritance pattern of many SPTLC2-related neuropathies

  • Tissue-specific conditional knockouts to distinguish primary neuronal effects from secondary consequences

• Phenotypic validation:

  • Assessment of multiple neurodegenerative markers (not just a single readout)

  • Correlation of biochemical changes with functional neurological parameters

  • Age-matched controls to account for temporal progression of neuropathic phenotypes

• Mechanistic controls:

  • Inclusion of sphingolipid synthesis inhibitors as complementary approaches

  • Manipulation of downstream metabolic pathways to establish causality

  • Rescue experiments with sphingolipid supplementation

• Translational controls:

  • Parallel studies in multiple model systems (e.g., rodent models alongside iPSC-derived neurons)

  • Validation in patient-derived samples where available

  • Correlation with clinical parameters from human studies

By incorporating these controls, researchers can establish more definitive relationships between SPTLC2 dysfunction and neuropathic mechanisms.

What cell lines are optimal for studying SPTLC2 function?

Selection of appropriate cell lines is crucial for SPTLC2 research. Based on validated antibody reactivity and expression data, recommended cell lines include:

*Not specifically mentioned in search results but relevant for neuropathy studies

For neurological studies, primary neurons or induced pluripotent stem cell (iPSC)-derived neurons may provide more physiologically relevant systems than immortalized cell lines. When selecting cell models, researchers should consider both the expression level of SPTLC2 and the presence of required cofactors and interacting proteins .

What are common issues with SPTLC2 antibody detection and how can these be resolved?

Researchers frequently encounter several challenges when working with SPTLC2 antibodies. Common issues and their solutions include:

• Weak signal in Western blot:

  • Increase protein loading (40-60 μg total protein)

  • Reduce antibody dilution (start with 1:1000)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use enhanced chemiluminescence substrates with higher sensitivity

  • Verify sample preparation protocol to ensure proper protein extraction from ER membranes

• Multiple bands or unexpected molecular weight:

  • Verify sample preparation (complete denaturation and reduction)

  • Check for post-translational modifications or alternative splicing

  • Include positive control samples with confirmed SPTLC2 expression

  • Consider using a different antibody targeting an alternative epitope

  • Run a peptide competition assay to identify specific versus non-specific bands

• High background in immunohistochemistry:

  • Increase antibody dilution (1:200-1:500)

  • Extend blocking time (2 hours at room temperature)

  • Use more stringent washing conditions

  • Optimize antigen retrieval conditions

  • Include additional blocking steps (avidin/biotin blocking for biotin-based detection systems)

• Inconsistent results between experiments:

  • Standardize lysate preparation methods

  • Use internal loading controls and normalization

  • Prepare larger batches of working antibody dilutions

  • Control for tissue fixation time in IHC applications

  • Consider lot-to-lot variations in antibodies and validate new lots

Maintaining detailed laboratory records of optimization steps and successful protocols will help establish reproducible conditions for SPTLC2 detection across experiments.

How can researchers quantify SPTLC2 protein levels accurately?

Accurate quantification of SPTLC2 requires attention to methodological details:

• Western blot quantification:

  • Use appropriate internal controls (housekeeping proteins that match SPTLC2's molecular weight range)

  • Establish a linear dynamic range for both SPTLC2 and control proteins

  • Apply mainstream densitometry software (ImageJ, Image Studio, etc.)

  • Normalize SPTLC2 signal to total protein stain rather than single housekeeping genes when possible

  • Run a concentration gradient to ensure measurements fall within the linear range

• ELISA/quantitative approaches:

  • Generate standard curves using recombinant SPTLC2 protein

  • Validate sample matrix effects

  • Account for extraction efficiency in different tissue types

  • Apply the same protein extraction protocol consistently across all experimental samples

  • Consider using new quantitative approaches like capillary western platforms for higher reproducibility

• Statistical considerations:

  • Perform at least three biological replicates

  • Apply appropriate statistical tests based on data distribution

  • Report both absolute and relative quantification values

  • Consider using ANOVA for multi-group comparisons rather than multiple t-tests

  • Report confidence intervals alongside p-values

When reporting quantitative SPTLC2 data, researchers should clearly describe the normalization method, the antibody dilution used, and the detection system employed to facilitate cross-study comparisons.

What are the latest methods for studying SPTLC2 protein-protein interactions?

Investigation of SPTLC2 protein interactions has evolved significantly with several cutting-edge approaches now available:

• Proximity-based methods:

  • BioID or TurboID approaches: Fusion of biotin ligase to SPTLC2 allows biotinylation of proximal proteins

  • APEX2 proximity labeling: Provides temporal control and subcellular resolution of interactions

  • Split-protein complementation assays: Useful for confirming suspected binary interactions

• Advanced co-immunoprecipitation approaches:

  • Quantitative SILAC-based co-IP: Allows discrimination between specific and non-specific interactors

  • Cross-linking mass spectrometry (XL-MS): Captures transient or weak interactions

  • Co-IP combined with targeted proteomics: Provides more sensitive detection of interaction partners

• Live cell interaction monitoring:

  • FRET/FLIM approaches using fluorescent protein-tagged SPTLC2

  • Split luciferase complementation assays for real-time interaction monitoring

  • Optogenetic approaches to induce or disrupt interactions with temporal control

• Structural biology integration:

  • Cryo-EM studies of SPTLC2-containing complexes

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to map interaction interfaces

  • Integrative structural biology combining multiple data types

These approaches provide complementary information about SPTLC2 interactions, with each offering distinct advantages for particular research questions.

How can CRISPR-Cas9 genome editing be applied to SPTLC2 research?

CRISPR-Cas9 technology has transformed SPTLC2 research, enabling precise genetic manipulation:

• Knockout approaches:

  • Complete gene knockout to study loss-of-function effects

  • Conditional knockout systems (e.g., floxed alleles with tissue-specific Cre expression)

  • Inducible knockout systems for temporal control of SPTLC2 depletion

• Knock-in strategies:

  • Introduction of disease-associated mutations to model pathological conditions

  • Addition of epitope tags for improved detection (e.g., FLAG, HA)

  • Generation of fluorescent protein fusions for live-cell imaging

• Regulatory element manipulation:

  • Targeting of SPTLC2 promoter or enhancer regions to study transcriptional regulation

  • CRISPRi/CRISPRa approaches for reversible repression or activation of SPTLC2 expression

  • Base editing to introduce specific regulatory sequence modifications

• High-throughput approaches:

  • CRISPR screens to identify genes affecting SPTLC2 function

  • Perturb-seq to examine transcriptional consequences of SPTLC2 manipulation at single-cell resolution

  • Combinatorial CRISPR approaches to study genetic interactions with SPTLC2

When applying CRISPR-Cas9 methods to SPTLC2 research, careful design of guide RNAs, validation of editing outcomes, and thorough characterization of resulting cellular phenotypes are essential for generating reliable and interpretable data.

What emerging imaging techniques are advancing SPTLC2 subcellular localization studies?

Visualization of SPTLC2 has benefited from recent advances in imaging technology:

• Super-resolution microscopy:

  • STORM/PALM approaches achieve 20-30 nm resolution to precisely localize SPTLC2 within ER subdomains

  • Expansion microscopy physically enlarges specimens to achieve effective super-resolution with standard confocal microscopy

  • Lattice light-sheet microscopy enables high-speed 3D imaging with reduced phototoxicity

• Live-cell imaging approaches:

  • CRISPR knock-in of fluorescent tags at the endogenous SPTLC2 locus for physiological expression levels

  • Split-GFP complementation to visualize SPTLC2 interactions in real-time

  • Photoactivatable or photoconvertible fluorescent proteins to track SPTLC2 dynamics

• Correlative techniques:

  • Correlative light and electron microscopy (CLEM) to combine immunofluorescence with ultrastructural analysis

  • Proximity ligation assay combined with super-resolution imaging

  • Mass spectrometry imaging to correlate SPTLC2 localization with lipid distribution

• Functional imaging:

  • FRET-based sensors to detect SPTLC2 enzymatic activity in situ

  • Fluorescent sphingolipid analogs to track metabolic products

  • Organelle-specific pH or calcium sensors to correlate SPTLC2 activity with cellular physiology

These advanced imaging approaches provide unprecedented insights into SPTLC2 localization and dynamics, facilitating a deeper understanding of its functional roles in health and disease contexts.